Every material Form 8-K Lilly (Eli) filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Eli Lilly's board elected Stanford University chemistry professor Carolyn R. Bertozzi as a new director, effective December 8, 2025. She will serve on the Science and Technology Committee and the Ethics and Compliance Committee, and must stand for shareholder election at the May 2026 annual meeting.
Board elected Dr. Carolyn R. Bertozzi, age 59, on November 18, 2025, effective December 8, 2025
Board determined she is independent under NYSE standards and company guidelines
She joins the Science and Technology Committee and the Ethics and Compliance Committee
Shareholders will vote on her election at the May 2026 annual meeting
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lilly (Eli) filing is on SEC EDGAR ↗. 8-K briefs of other companies →